Positioning Ketamir-2 for an initial IND submission in the fourth quarter of 2024 and MIRA-55 in the first half of 2025.
| MIRA1a | Pre-Clinical | IND | Phase 1 | Phase 2 | Phase 3 |
|---|---|---|---|---|---|
MIRA-55Anxiety & Cognitive Decline in early stage dementia patients |
Pre-Clinical Phase in progress
|
IND Phase not started
|
Phase 1 Phase not started
|
Phase 2 Phase not started
|
Phase 3 Phase not started
|
MIRA-55Neuropathic Pain |
Pre-Clinical Phase in progress
|
IND Phase not started
|
Phase 1 Phase not started
|
Phase 2 Phase not started
|
Phase 3 Phase not started
|
Ketamir-2Treatment Resistant Depression (TRD) |
Pre-Clinical Phase in progress
|
IND Phase not started
|
Phase 1 Phase not started
|
Phase 2 Phase not started
|
Phase 3 Phase not started
|
Ketamir-2Major Depressive Disorder with Suicidal Ideation (MDDSI) |
Pre-Clinical Phase in progress
|
IND Phase not started
|
Phase 1 Phase not started
|
Phase 2 Phase not started
|
Phase 3 Phase not started
|